期刊文献+

局限型和严重型韦格纳肉芽肿病的临床特征分析 被引量:1

Limited and severe Wegener's granulomatosis:clinical features
下载PDF
导出
摘要 目的比较局限型韦格纳肉芽肿病(WG)与严重型WG患者的临床特征、实验室检查和对治疗反应的差异。方法回顾性比较14例局限型WG与15例严重型WG患者临床特征、实验室检查和治疗反应之间的差异。结果与严重型WG比较,局限型WG患者发病年龄小[(41±14)岁与(62±12)岁,P<0.01],女性所占比例高(64%与22%,P=0.033)。严重型WG贫血发生率高(87%与43%,P=0.013),红细胞沉降率高的比例大(93%与64%,P=0.046)、抗中性粒细胞胞质抗体(ANCA)阳性率高(57%与93%,P=0.023)、胞质型抗中性粒细胞胞质抗体(cANCA)阳性率高(43%与80%,P=0.039)、蛋白酶3(PR3)阳性率高(36%与80%,P=0.016)。局限型WG对标准方案的诱导缓解率高(87%与46%,P=0.027),并且平均诱导缓解时间短[(5.6±0.7)个月与(11.5±3.4)个月P<0.01]。结论局限型WG和重型WG在年龄、性别和临床特征方面有差异。标准治疗对局限型WG的诱导缓解率高,诱导缓解期短。严重型WG应选择更积极的免疫抑制治疗。 Objective To compare the clinical and laboratory features and treatment response between limited and severe Wegener's granulomatosis(WG).Methods All available data from patients with a confirmed diagnosis of limited WG(n=14) and severe WG(n=15) were retrospectively reviewed.Results There were significant differences between patients with limited WG and those with severe WG with regard to age(41±14 vs 62±12 yr,P〈0.001) and female gender(64% vs 22%,P=0.033).The prevalence of anemia(43% vs 87%,P=0.013) was significantly lower in limited than in severe WG.More severe WG cases were found to be associated with increased erythrocyte sedimentation rate(93% vs 64%,P=0.046),positive ANCA rate(93% vs 57%,P=0.023),positive cANCA rate(80% vs 43%,P= 0.039) and positive PR3 rate(80% vs 36%,P=0.016).The remission induction rate was higher in limited WG than that in severe WG(87%vs 46%,P=0.027).The mean time to remission induction in severe WG was longer than that in limited WG(5.6±0.7 vs 11.5±3.4 months,P〈0.01).Conclusion There were significant differences between patients with limited WG and those with severe WG with regard to age,sex and clinical features.Limited WG showed a higher rate of remission induction and a shorter duration of remission induction than as for severe WG with standard treatment.More aggressive immunodepressant should be employed in severe WG.
出处 《中国药物与临床》 CAS 2010年第5期489-492,共4页 Chinese Remedies & Clinics
基金 广东省科技计划项目(2007B031500007)
关键词 韦格纳肉芽肿病 症状和体征 疾病严重程度指数 Wegener gramulmatosis Signs and symptoms Disease severity index
  • 相关文献

参考文献6

  • 1Jayne D. Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol,2001,13:48-55.
  • 2The Wegener's Granulomatosis Etanereept Trial Research Group. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum,2003,48: 2299-2309.
  • 3Sneller MC, Hoffmann GS,Talar-Williams C, et al. An analysis of forty-two Wegener' s granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum, 1995,38:608-613.
  • 4Chen FM,Zhang YY,Zhao MH. Cinical and pathological characteristics of Chinese patients with antineutrophil cytoplasmic autoantibody associated systemic vasculitides: a study of 426 patients from a single centre. Postgrad Med J, 2005,81:723-727.
  • 5Richard A, Watts l, David G. Epidemiology of the vasculitides. Semin Respir Crit Care Med, 2004,25(5):455-464.
  • 6The European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis,2009,68:10-317.

同被引文献13

  • 1Popa ER, Stegeman CA, Kallenberg CG, et al. Staphylococcus aureus and Wegener's granulomatosis [J]. Arthritis Res, 2002,4 : 77-79.
  • 2Christof VE, Karsten B, Konstanze M, et al. Nasal Carriage as a Source of Staphylococcus aureus Bacteremia[J]. N Engl J Med,2001,344 :11-16.
  • 3Zycinska K, Wardyn KA, Zielonka TM, et al. Chronic crusting, nasal carriage of Staphylococcus aureus and relapse rate in pulmonary Wegener's granulomatosis [J] . J Physiol Pharmacol, 2008, 59 ( Suppl 6): 825-831.
  • 4Joshi L, Hamour S, Salama AD, et al. Renal and ocular targets for therapy in Wegener' s granulomatosis[J]. Inflamm Allergy Drug Targets, 2009,8: 70-79.
  • 5Marzano AV, Balice Y, Papini M, et al. Localized Wegenerrs granulomatosis[J]. J Eur Acad Dermatol Venereol, 2011,25 : 1466-1470.
  • 6Jayne D. Update on the European Vasculitis Study Group trials [J] . Curr Opin Rheumatol, 2001, 13: 48-55.
  • 7The Wegener's Granulomatosis Etanercept Trial Research Group. Limited versus severe Wegener' s granulomatosis: baseline data on patients in the Wegener' s granulomatosis etanercept trial [J]. Arthritis Rheum, 2003,48 : 2299-2309.
  • 8Mlika M, Ayadi-Kaddour A, Marghli A, et al. Pulmonary localization revealing Wegener' s granulomatosis [J]. Scientific World Journal, 2010, 10:806-810.
  • 9StegemanCA, Tervaert JW, de Jong PE, etal. Trimethoprim-sulfamethoxazole for the prevention of relapses of Wegener's granulomatosis. Dutch Co- Trimoxazole Wegener Study Group[J]. New Engl J Med, 1996,335 : 16-20.
  • 10Roberts DE,Curd JG. Sulfonamides as anti- inflammatory agents in the treatment of Wegener's granulomatosis [ J ] . Arthritis Rheum, 1990, 33 1590-1593.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部